{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:04:18Z","timestamp":1790215458771,"version":"4.1.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC0627"],"award-info":[{"award-number":["2024NSFSC0627"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117418","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:50:47Z","timestamp":1760223047000},"page":"117418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P4","title":["Bromodomain containing protein 4 (BRD4) and cancer therapy: A glimpse at dual-target drug development"],"prefix":"10.1016","volume":"242","author":[{"given":"Zixiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3900-9486","authenticated-orcid":false,"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bcp.2025.117418_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202100180","article-title":"BRD4 in physiology and pathology: \u201cBET\u201d on its partners","volume":"43","author":"Liang","year":"2021","journal-title":"Bioessays"},{"key":"10.1016\/j.bcp.2025.117418_b0010","doi-asserted-by":"crossref","unstructured":"O. Gilan, I. Rioja, K. Knezevic, M.J. Bell, M.M. Yeung, N.R. Harker, E.Y.N. Lam, C.W. Chung, P. Bamborough, M. Petretich, M. Urh, S.J. Atkinson, A.K. Bassil, E.J. Roberts, D. Vassiliadis, M.L. Burr, A.G.S. Preston, C. Wellaway, T. Werner, J.R. Gray, A.M. Michon, T. Gobbetti, V. Kumar, P.E. Soden, A. Haynes, J. Vappiani, D.F. Tough, S. Taylor, S.J. Dawson, M. Bantscheff, M. Lindon, G. Drewes, E.H. Demont, D.L. Daniels, P. Grandi, R.K. Prinjha, M.A. Dawson, Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation, Science (New York, N.Y.) 368(6489) (2020) 387-394.","DOI":"10.1126\/science.aaz8455"},{"key":"10.1016\/j.bcp.2025.117418_b0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2022.12.035","article-title":"Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy","volume":"354","author":"He","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bcp.2025.117418_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: Biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.bcp.2025.117418_b0025","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41588-021-00934-8","article-title":"BRD4 orchestrates genome folding to promote neural crest differentiation","volume":"53","author":"Linares-Saldana","year":"2021","journal-title":"Nat. Genet."},{"issue":"7327","key":"10.1016\/j.bcp.2025.117418_b0030","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0035","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.drudis.2021.08.007","article-title":"Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: current situation and future directions","volume":"27","author":"Jin","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"7794","key":"10.1016\/j.bcp.2025.117418_b0040","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.bcp.2025.117418_b0045","doi-asserted-by":"crossref","first-page":"E1072","DOI":"10.1073\/pnas.1613091114","article-title":"Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis","volume":"114","author":"Andrews","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0050","doi-asserted-by":"crossref","first-page":"16272","DOI":"10.1038\/s41598-017-16588-8","article-title":"Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal (ET) Domain of BRD4","volume":"7","author":"Konuma","year":"2017","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.bcp.2025.117418_b0055","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1073\/pnas.1516813113","article-title":"Structure of the Brd4 ET domain bound to a C-terminal motif from \u03b3-retroviral integrases reveals a conserved mechanism of interaction","volume":"113","author":"Crowe","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0060","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","article-title":"Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets","volume":"9","author":"Qian","year":"2023","journal-title":"Cell Death Discov"},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0065","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/15592294.2015.1034416","article-title":"Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma","volume":"10","author":"Sengupta","year":"2015","journal-title":"Epigenetics"},{"issue":"20","key":"10.1016\/j.bcp.2025.117418_b0070","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1158\/0008-5472.CAN-21-0649","article-title":"miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4","volume":"81","author":"Gen","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117418_b0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41698-020-0108-z","article-title":"Super-enhancer function and its application in cancer targeted therapy","volume":"4","author":"Tang","year":"2020","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and Cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.117418_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1042490","article-title":"Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme","volume":"11","author":"Ye","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2025.117418_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106767","article-title":"BRD4: New hope in the battle against glioblastoma","volume":"191","author":"Duan","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"16","key":"10.1016\/j.bcp.2025.117418_b0095","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.molcel.2023.06.032","article-title":"Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation","volume":"83","author":"Zheng","year":"2023","journal-title":"Mol. Cell"},{"issue":"17","key":"10.1016\/j.bcp.2025.117418_b0100","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1016\/j.molcel.2021.06.026","article-title":"A BRD4-mediated elongation control point primes transcribing RNA polymerase II for 3'-processing and termination","volume":"81","author":"Arnold","year":"2021","journal-title":"Mol. Cell"},{"issue":"14","key":"10.1016\/j.bcp.2025.117418_b0105","doi-asserted-by":"crossref","first-page":"9040","DOI":"10.1074\/jbc.M707603200","article-title":"The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase","volume":"283","author":"Mochizuki","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/nar\/gkw826","article-title":"BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire","volume":"45","author":"Najafova","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41594-020-0394-8","article-title":"Roles of the BRD4 short isoform in phase separation and active gene transcription","volume":"27","author":"Han","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-021-01424-5","article-title":"The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis","volume":"20","author":"Drumond-Bock","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.117418_b0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.18632\/genesandcancer.233","article-title":"Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma","volume":"14","author":"Drumond-Bock","year":"2023","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bcp.2025.117418_b0130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2020.10.016","article-title":"Triple-negative breast cancer therapeutic resistance: where is the Achilles' heel?","volume":"497","author":"Bai","year":"2021","journal-title":"Cancer Lett."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2025.117418_b0135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/21541264.2022.2108302","article-title":"BRD4: a general regulator of transcription elongation","volume":"13","author":"Altendorfer","year":"2022","journal-title":"Transcription"},{"key":"10.1016\/j.bcp.2025.117418_b0140","doi-asserted-by":"crossref","unstructured":"R.K. Modukuri, Z. Yu, Z. Tan, H.M. Ta, M.N. Ucisik, Z. Jin, J.L. Anglin, K.L. Sharma, P. Nyshadham, F. Li, K. Riehle, J.C. Faver, K. Duong, S. Nagarajan, N. Simmons, S.S. Palmer, M. Teng, D.W. Young, J.S. Yi, C. Kim, M.M. Matzuk, Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections, Proceedings of the National Academy of Sciences of the United States of America 119(22) (2022) e2122506119.","DOI":"10.1073\/pnas.2122506119"},{"issue":"3","key":"10.1016\/j.bcp.2025.117418_b0145","article-title":"The converging roles of BRD4 and gene transcription in pluripotency and oncogenesis","volume":"2","author":"Wu","year":"2015","journal-title":"RNA Dis"},{"issue":"40","key":"10.1016\/j.bcp.2025.117418_b0150","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7370","key":"10.1016\/j.bcp.2025.117418_b0155","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0160","first-page":"506","article-title":"Targeting Super-Enhancers for Disease Treatment and Diagnosis","volume":"41","author":"Shin","year":"2018","journal-title":"Mol. Cells"},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0165","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bcp.2025.117418_b0170","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1093\/nar\/gku449","article-title":"Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation","volume":"42","author":"Itzen","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0175","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s13402-020-00537-1","article-title":"BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways","volume":"43","author":"Zhang","year":"2020","journal-title":"Cell. Oncol. (Dordr.)"},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0180","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41418-019-0353-2","article-title":"Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail","volume":"27","author":"Lu","year":"2020","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.bcp.2025.117418_b0185","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/tox.22873","article-title":"BRD4 promotes glioma cell stemness via enhancing miR-142-5p-mediated activation of Wnt\/\u03b2-catenin signaling","volume":"35","author":"Wang","year":"2020","journal-title":"Environ. Toxicol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117418_b0190","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/1878-0261.13368","article-title":"ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD","volume":"17","author":"Qian","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bcp.2025.117418_b0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejphar.2019.03.018","article-title":"BRD4 promotes the stemness of gastric cancer cells via attenuating miR-216a-3p-mediated inhibition of Wnt\/\u03b2-catenin signaling","volume":"852","author":"Song","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117418_b0200","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112034","article-title":"BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer","volume":"392","author":"Jing","year":"2020","journal-title":"Exp. Cell Res."},{"issue":"11","key":"10.1016\/j.bcp.2025.117418_b0210","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0215","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1038\/s41598-022-08356-0","article-title":"Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients","volume":"12","author":"Bruns","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0220","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12964-023-01319-6","article-title":"BRD4\/nuclear PD-L1\/RelB circuit is involved in the stemness of breast cancer cells","volume":"21","author":"Kim","year":"2023","journal-title":"Cell Commun. Signal"},{"issue":"12","key":"10.1016\/j.bcp.2025.117418_b0225","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1158\/2159-8290.CD-23-0601","article-title":"p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression","volume":"13","author":"Efe","year":"2023","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0230","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s44319-023-00033-1","article-title":"BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma","volume":"25","author":"Das","year":"2024","journal-title":"EMBO Rep."},{"issue":"12","key":"10.1016\/j.bcp.2025.117418_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20122887","article-title":"Telomerase and Telomeres Biology in Thyroid Cancer","volume":"20","author":"Donati","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.bcp.2025.117418_b0240","doi-asserted-by":"crossref","first-page":"8403","DOI":"10.1093\/nar\/gkx561","article-title":"BRD4 inhibitors block telomere elongation","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.bcp.2025.117418_b0245","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0250","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41556-022-00842-x","article-title":"Telomere dysfunction in ageing and age-related diseases","volume":"24","author":"Rossiello","year":"2022","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0255","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117418_b0260","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1039\/C8MD00198G","article-title":"Targeting Brd4 for cancer therapy: inhibitors and degraders","volume":"9","author":"Duan","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.bcp.2025.117418_b0265","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ebiom.2019.04.006","article-title":"Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer","volume":"43","author":"Mustafi","year":"2019","journal-title":"EBioMedicine"},{"issue":"7570","key":"10.1016\/j.bcp.2025.117418_b0270","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bcp.2025.117418_b0275","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0280","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1038\/s41467-020-16170-3","article-title":"Acquired resistance to combined BET and CDK4\/6 inhibition in triple-negative breast cancer","volume":"11","author":"Ge","year":"2020","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.bcp.2025.117418_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174079","article-title":"BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in patients with selected Advanced Solid Tumors: results from a phase 1\/2a Trial","volume":"14","author":"Hilton","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0290","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.annonc.2020.03.294","article-title":"Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed\/refractory non-Hodgkin's lymphoma","volume":"31","author":"Moreno","year":"2020","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117418_b0295","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018762","article-title":"Writers and readers of histone acetylation: structure, mechanism, and inhibition","volume":"6","author":"Marmorstein","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0300","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"29","key":"10.1016\/j.bcp.2025.117418_b0305","doi-asserted-by":"crossref","first-page":"11497","DOI":"10.1021\/jacs.9b02738","article-title":"Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in living Cells","volume":"141","author":"Li","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0310","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1158\/1078-0432.CCR-18-4071","article-title":"Development of 2 Bromodomain and Extraterminal Inhibitors with Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117418_b0315","first-page":"4048","article-title":"Preliminary results from an Ongoing phase 1\/2 Study of INCB057643, a Bromodomain and Extraterminal (BET) Protein Inhibitor, in patients (pts) with Advanced Malignancies","volume":"130","author":"Forero-Torres","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117418_b0320","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2018.12.020","article-title":"First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic\/pharmacodynamic relationship and early termination due to unexpected toxicity","volume":"109","author":"Postel-Vinay","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0325","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1078-0432.CCR-22-1284","article-title":"A phase I\/II Open-Label Study of Molibresib for the Treatment of Relapsed\/Refractory Hematologic Malignancies","volume":"29","author":"Dawson","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0330","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors","volume":"4","author":"Piha-Paul","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0335","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-23-0133","article-title":"A phase I\/II Study of GSK525762 combined with Fulvestrant in patients with Hormone Receptor-positive\/HER2-negative Advanced or Metastatic Breast Cancer","volume":"30","author":"Cescon","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0340","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/ijc.33861","article-title":"Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: results of a phase I\/II open-label, dose escalation study","volume":"150","author":"Cousin","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"15","key":"10.1016\/j.bcp.2025.117418_b0345","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood.2019002922","article-title":"Mechanistic basis and efficacy of targeting the \u03b2-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors","volume":"135","author":"Saenz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2025.117418_b0350","doi-asserted-by":"crossref","DOI":"10.1111\/ejn.16499","article-title":"Impact of JQ1 treatment on seizures, hippocampal gene expression, and gliosis in a mouse model of temporal lobe epilepsy","author":"Harnett","year":"2024","journal-title":"Eur. J. Neurosci."},{"issue":"7586","key":"10.1016\/j.bcp.2025.117418_b0355","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0360","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.molcel.2020.04.027","article-title":"Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-negative Breast Cancer","volume":"78","author":"Shu","year":"2020","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.bcp.2025.117418_b0365","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/nm.4378","article-title":"Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4","volume":"23","author":"Dai","year":"2017","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0370","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.molcel.2018.06.036","article-title":"DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4","volume":"71","author":"Jin","year":"2018","journal-title":"Mol. Cell"},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0375","first-page":"1217","article-title":"Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling","volume":"15","author":"T\u00f6gel","year":"2016","journal-title":"Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells, Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.bcp.2025.117418_b0380","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/s41416-023-02464-y","article-title":"The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma","volume":"129","author":"Kuang","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0385","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.apsb.2019.10.003","article-title":"Targeting autophagy-related protein kinases for potential therapeutic purpose","volume":"10","author":"Xiang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"11_Supplement","key":"10.1016\/j.bcp.2025.117418_b0390","doi-asserted-by":"crossref","first-page":"C244","DOI":"10.1158\/1535-7163.TARG-13-C244","article-title":"Abstract C244: Development of the BET bromodomain inhibitor OTX015","volume":"12","author":"Noel","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bcp.2025.117418_b0395","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40262-015-0327-6","article-title":"Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in patients with Haematologic Malignancies","volume":"55","author":"Odore","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"30","key":"10.1016\/j.bcp.2025.117418_b0400","first-page":"3007","article-title":"Phase Ib Trial with Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins","volume":"36","author":"Lewin","year":"2018","journal-title":"Patients with Selected Advanced Solid Tumors, J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0405","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s41418-021-00913-w","article-title":"SPOP mutations promote p62\/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer","volume":"29","author":"Shi","year":"2022","journal-title":"Cell Death Differ."},{"issue":"9","key":"10.1016\/j.bcp.2025.117418_b0410","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/nm.4379","article-title":"Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0415","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s12935-021-02160-y","article-title":"The role of the deubiquitinating enzyme DUB3\/USP17 in cancer: a narrative review","volume":"21","author":"Yang","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"11","key":"10.1016\/j.bcp.2025.117418_b0420","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/s41418-019-0303-z","article-title":"DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell Death Differ."},{"issue":"43","key":"10.1016\/j.bcp.2025.117418_b0425","doi-asserted-by":"crossref","first-page":"75127","DOI":"10.18632\/oncotarget.20561","article-title":"Stabilization of the transcription factors slug and twist by the deubiquitinase dub3 is a key requirement for tumor metastasis","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117418_b0430","article-title":"Post-Translational modifications of BRD4: Therapeutic Targets for Tumor","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"17\u201318","key":"10.1016\/j.bcp.2025.117418_b0435","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1101\/gad.315648.118","article-title":"Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4\/6is","volume":"32","author":"Liao","year":"2018","journal-title":"Genes Dev."},{"issue":"8","key":"10.1016\/j.bcp.2025.117418_b0440","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1158\/0008-5472.CAN-23-1749","article-title":"Cotargeting CDK4\/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117418_b0445","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ddtec.2016.05.003","article-title":"Phospho-BRD4: transcription plasticity and drug targeting","volume":"19","author":"Chiang","year":"2016","journal-title":"Drug Discov. Today Technol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0450","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1038\/s41467-021-24687-4","article-title":"Stromal induction of BRD4 phosphorylation results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117418_b0455","doi-asserted-by":"crossref","unstructured":"P. Rathert, M. Roth, T. Neumann, F. Muerdter, J.S. Roe, M. Muhar, S. Deswal, S. Cerny-Reiterer, B. Peter, J. Jude, T. Hoffmann, M. Bory\u0144 \u0141, E. Axelsson, N. Schweifer, U. Tontsch-Grunt, L.E. Dow, D. Gianni, M. Pearson, P. Valent, A. Stark, N. Kraut, C.R. Vakoc, J. Zuber, Transcriptional plasticity promotes primary and acquired resistance to BET inhibition, Nature 525(7570) (2015) 543-547.","DOI":"10.1038\/nature14898"},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0460","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.cmet.2025.01.002","article-title":"Lactate controls cancer stemness and plasticity through epigenetic regulation","volume":"37","author":"Nguyen","year":"2025","journal-title":"Cell Metab."},{"issue":"15","key":"10.1016\/j.bcp.2025.117418_b0465","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1021\/acs.jmedchem.1c00683","article-title":"Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117418_b0470","doi-asserted-by":"crossref","DOI":"10.1002\/med.22057","article-title":"Rethinking therapeutic strategies of dual-target drugs: an update on pharmacological small-molecule compounds in cancer","author":"Yang","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0475","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/med.21398","article-title":"Targeting Programmed Cell Death using Small-Molecule Compounds to Improve potential Cancer Therapy","volume":"36","author":"Ke","year":"2016","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0480","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bcp.2025.117418_b0485","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3389\/fphar.2020.01043","article-title":"A Bromodomain-Containing Protein 4 (BRD4) Inhibitor Suppresses Angiogenesis by Regulating AP-1 Expression","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117418_b0490","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1021\/jm301522m","article-title":"Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors","volume":"56","author":"Morales","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0495","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.bbrc.2017.11.062","article-title":"Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth invitro and invivo","volume":"495","author":"Shen","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2025.117418_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.766888","article-title":"Preclinical Evaluation of a Novel dual Targeting PI3K\u03b4\/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia","volume":"11","author":"Ruan","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2025.117418_b0505","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2022.12.055","article-title":"Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma","volume":"354","author":"Sethi","year":"2023","journal-title":"J. Control. Release"},{"issue":"24","key":"10.1016\/j.bcp.2025.117418_b0510","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1080\/15384101.2017.1388973","article-title":"SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors","volume":"16","author":"Dai","year":"2017","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.bcp.2025.117418_b0515","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP Axis in Lethal Prostate Cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov."},{"issue":"23","key":"10.1016\/j.bcp.2025.117418_b0520","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1038\/s41388-022-02327-5","article-title":"Targeting CDCP1 gene transcription coactivated by BRD4 and CBP\/p300 in castration-resistant prostate cancer","volume":"41","author":"Ji","year":"2022","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.bcp.2025.117418_b0525","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910659","article-title":"The novel BET-CBP\/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer","volume":"11","author":"Yan","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0530","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116764119","article-title":"XP-524 is a dual-BET\/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer","volume":"119","author":"Principe","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"24","key":"10.1016\/j.bcp.2025.117418_b0535","doi-asserted-by":"crossref","first-page":"18025","DOI":"10.1021\/acs.jmedchem.1c01382","article-title":"Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4\/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-negative Breast Cancer Therapy","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2025.117418_b0540","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","article-title":"BRD4 Inhibition is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency","volume":"33","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0545","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","article-title":"Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bcp.2025.117418_b0550","doi-asserted-by":"crossref","unstructured":"X. Peng, X. Huang, S. Zhang, N. Zhang, S. Huang, Y. Wang, Z. Zhong, S. Zhu, H. Gao, Z. Yu, X. Yan, Z. Tao, Y. Dai, Z. Zhang, X. Chen, F. Wang, F.X. Claret, M. Elkabets, N. Ji, Y. Zhong, D. Kong, Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for Glioblastoma, Adv Sci (Weinh) (2024) e2307747.","DOI":"10.1002\/advs.202307747"},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0555","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.apsb.2020.06.003","article-title":"Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy","volume":"11","author":"Chang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"9","key":"10.1016\/j.bcp.2025.117418_b0560","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/acs.jmedchem.2c00135","article-title":"Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET\/PARP1 Inhibitors that Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-negative Breast Cancer Therapy","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bcp.2025.117418_b0565","doi-asserted-by":"crossref","first-page":"17413","DOI":"10.1021\/acs.jmedchem.1c01535","article-title":"Discovery of Potent and Novel dual PARP\/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117418_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114116","article-title":"Design, synthesis and mechanism studies of novel dual PARP1\/BRD4 inhibitors against pancreatic cancer","volume":"230","author":"Huang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0575","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0580","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"22","key":"10.1016\/j.bcp.2025.117418_b0585","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","article-title":"Epigenetic Alterations and Mechanisms that Drive Resistance to Targeted Cancer Therapies","volume":"81","author":"Wajapeyee","year":"2021","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0590","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: a versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0595","doi-asserted-by":"crossref","DOI":"10.3390\/genes12020208","article-title":"Novel Approaches to Epigenetic Therapies: from Drug Combinations to Epigenetic Editing","volume":"12","author":"Majchrzak-Celi\u0144ska","year":"2021","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0600","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-022-01078-9","article-title":"The role of histone modifications: from neurodevelopment to neurodiseases","volume":"7","author":"Park","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2025.117418_b0605","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s12276-020-00542-2","article-title":"LSD1: more than demethylation of histone lysine residues","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"9","key":"10.1016\/j.bcp.2025.117418_b0610","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s12276-021-00673-0","article-title":"Bromodomain proteins: protectors against endogenous DNA damage and facilitators of genome integrity","volume":"53","author":"Lee","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117418_b0615","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.apsb.2024.12.037","article-title":"BRD4 regulates m(6)A of ESPL1 mRNA via interaction with ALKBH5 to modulate breast cancer progression","volume":"15","author":"Zhang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0620","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2025.117418_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112426","article-title":"Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery","volume":"200","author":"Liang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2025.117418_b0630","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","article-title":"Drug Discovery Targeting Bromodomain-Containing Protein 4","volume":"60","author":"Liu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117418_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","article-title":"Epigenetic modifications: Key players in cancer heterogeneity and drug resistance","volume":"39","author":"Sadida","year":"2024","journal-title":"Transl. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0640","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/jrr\/rrt227","article-title":"Chromatin-regulating proteins as targets for cancer therapy","volume":"55","author":"Oike","year":"2014","journal-title":"J. Radiat. Res."},{"issue":"10","key":"10.1016\/j.bcp.2025.117418_b0645","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/ijc.33137","article-title":"Characterization of a dual BET\/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma","volume":"147","author":"Zhang","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2025.117418_b0650","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/nm.3952","article-title":"Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma","volume":"21","author":"Mazur","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0655","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011089","article-title":"Oncolytic strategy using new bifunctional HDACs\/BRD4 inhibitors against virus-associated lymphomas","volume":"19","author":"Chen","year":"2023","journal-title":"PLoS Pathog."},{"issue":"7","key":"10.1016\/j.bcp.2025.117418_b0660","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1021\/acs.jmedchem.9b02178","article-title":"Discovery of Thieno[2,3-d]pyrimidine-based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4\/Histone Deacetylase dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells","volume":"63","author":"Pan","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0665","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1021\/acschembio.3c00427","article-title":"Development of Potent dual BET\/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization","volume":"19","author":"Bauer","year":"2024","journal-title":"ACS Chem. Biol."},{"issue":"17","key":"10.1016\/j.bcp.2025.117418_b0670","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1016\/j.bmcl.2017.07.054","article-title":"Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4\/HDAC inhibitors","volume":"27","author":"Shao","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117418_b0675","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bioorg.2018.12.011","article-title":"Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC\/BRD4 dual inhibitors and anti-leukemia agents","volume":"84","author":"Cheng","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2025.117418_b0680","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1002\/anie.201915896","article-title":"Potent dual BET\/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer","volume":"59","author":"He","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bcp.2025.117418_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117386","article-title":"Design, synthesis and mechanism studies of dual EZH2\/BRD4 inhibitors for cancer therapy","volume":"91","author":"Chen","year":"2023","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0690","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2025.117418_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101131","article-title":"YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2(Y641mut) germinal center-derived lymphoma","volume":"61","author":"Chamorro-Jorganes","year":"2025","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.bcp.2025.117418_b0700","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1021\/acs.jmedchem.1c01876","article-title":"Design and Synthesis of dual EZH2\/BRD4 Inhibitors to Target Solid Tumors","volume":"65","author":"Guo","year":"2022","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0705","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1021\/acs.jmedchem.2c01607","article-title":"Design, Synthesis, and Biological Evaluation of a Potent dual EZH2-BRD4 Inhibitor for the Treatment of some Solid Tumors","volume":"66","author":"Huang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2025.117418_b0710","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202100519","article-title":"Mechanistic Insights into the Selective dual BET and PLK1 Inhibitory activity of a Novel Benzamide compound in Castration-Resistant Prostrate Cancer","volume":"18","author":"Akawa","year":"2021","journal-title":"Chem. Biodivers."},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0715","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1535-7163.MCT-19-0578","article-title":"Novel dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription factor Function and Inducing Mitotic Abnormality","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117418_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117609","article-title":"Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer","volume":"101","author":"Liu","year":"2024","journal-title":"Bioorg. Med. Chem."},{"issue":"17","key":"10.1016\/j.bcp.2025.117418_b0725","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.1021\/acs.jmedchem.8b00765","article-title":"Structure-Guided Design and Development of Potent and Selective dual Bromodomain 4 (BRD4)\/Polo-like Kinase 1 (PLK1) Inhibitors","volume":"61","author":"Liu","year":"2018","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2025.117418_b0730","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.tranon.2019.09.013","article-title":"Small-Molecule dual PLK1 and BRD4 Inhibitors are active against Preclinical Models of Pediatric Solid Tumors","volume":"13","author":"Timme","year":"2020","journal-title":"Transl. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117418_b0735","article-title":"Novel Aminopyrimidine-2,4-diones, 2-Thiopyrimidine-4-ones, and 6-Arylpteridines as Dual-Target Inhibitors of BRD4\/PLK1: Design","volume":"16","author":"El-Kalyoubi","year":"2023","journal-title":"Synthesis, Cytotoxicity, and Computational Studies, Pharmaceuticals (basel, Switzerland)"},{"key":"10.1016\/j.bcp.2025.117418_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112152","article-title":"Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1\/BRD4 inhibitors","volume":"191","author":"Wang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117418_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117886","article-title":"Achieving dual-target fluorescent probes for tracing and inhibiting BRD4\/PLK1 in tumor cells and tissues synchronously","volume":"296","author":"Gao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bcp.2025.117418_b0750","doi-asserted-by":"crossref","first-page":"9787","DOI":"10.1021\/acs.jmedchem.0c00962","article-title":"Rational Design and Evaluation of 6-(Pyrimidin-2-ylamino)-3,4-dihydroquinoxalin-2(1H)-ones as Polypharmacological Inhibitors of BET and Kinases","volume":"63","author":"Lv","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117418_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116009","article-title":"Design and synthesis of dual BRD4\/Src inhibitors for treatment of triple-negative breast cancer","volume":"264","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117418_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106386","article-title":"Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2\/BRD4(BD2) dual target inhibitors","volume":"132","author":"Guo","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2025.117418_b0765","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1021\/acs.jmedchem.8b01947","article-title":"Designing dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity","volume":"62","author":"Watts","year":"2019","journal-title":"J. Med. Chem."},{"issue":"33","key":"10.1016\/j.bcp.2025.117418_b0770","doi-asserted-by":"crossref","first-page":"53997","DOI":"10.18632\/oncotarget.9804","article-title":"Targeting BET bromodomain proteins in solid tumors","volume":"7","author":"Sahai","year":"2016","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.bcp.2025.117418_b0775","doi-asserted-by":"crossref","first-page":"17698","DOI":"10.18632\/oncotarget.4131","article-title":"BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells","volume":"6","author":"Coud\u00e9","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0780","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0785","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00280-022-04483-7","article-title":"An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16","volume":"90","author":"Ma","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117418_b0790","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.celrep.2018.02.011","article-title":"Resistance to BET Inhibitor leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer","volume":"22","author":"Pawar","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0795","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-024-00483-w","article-title":"The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt\/\u03b2-catenin signaling","volume":"13","author":"Marr","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117418_b0800","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0805","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1081\/DMR-200028812","article-title":"Drug bioactivation, covalent binding to target proteins and toxicity relevance","volume":"37","author":"Zhou","year":"2005","journal-title":"Drug Metab. Rev."},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0810","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0815","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0820","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bcp.2025.117418_b0825","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7327","key":"10.1016\/j.bcp.2025.117418_b0830","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117418_b0835","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: At the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2025.117418_b0840","article-title":"Bromodomain inhibition of the transcriptional coactivators CBP\/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma","volume":"5","author":"Conery","year":"2016","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.bcp.2025.117418_b0845","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nm.4372","article-title":"Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors","volume":"23","author":"Janouskova","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0850","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET Proteins as Targets for Anticancer Treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0855","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-023-02615-2","article-title":"The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma","volume":"42","author":"Feng","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0860","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.apsb.2022.02.009","article-title":"A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization","volume":"12","author":"Yang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0865","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev-pharmtox-030624-110238","article-title":"PROTACs as Therapeutic Modalities for Drug Discovery in Castration-Resistant Prostate Cancer","volume":"65","author":"Wang","year":"2025","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bcp.2025.117418_b0870","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6241","key":"10.1016\/j.bcp.2025.117418_b0875","first-page":"1376","article-title":"DRUG DEVELOPMENT","volume":"348","author":"Winter","year":"2015","journal-title":"Phthalimide Conjugation as a Strategy for in Vivo Target Protein Degradation, Science"},{"issue":"26","key":"10.1016\/j.bcp.2025.117418_b0880","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.bcp.2025.117418_b0885","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3Ubiquitin Ligase Cereblon to Efficiently Target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117418_b0890","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.7150\/thno.102531","article-title":"A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2025.117418_b0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123387","article-title":"Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy","volume":"322","author":"Li","year":"2025","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bcp.2025.117418_b0900","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jmedchem.4c02047","article-title":"Modulating the Potency of BRD4 PROTACs at the Systems Level with Amine-Acid Coupling Reactions","volume":"68","author":"McGrath","year":"2025","journal-title":"J. Med. Chem."},{"issue":"7973","key":"10.1016\/j.bcp.2025.117418_b0905","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-023-06348-2","article-title":"Rewiring cancer drivers to activate apoptosis","volume":"620","author":"Gourisankar","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117418_b0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibs.2025.07.005","article-title":"Exploring nondegrading molecular glues for protein-protein interactions","author":"Yu","year":"2025","journal-title":"Trends Biochem. Sci"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T01:35:06Z","timestamp":1769477706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225006835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":182,"alternative-id":["S0006295225006835"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117418","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bromodomain containing protein 4 (BRD4) and cancer therapy: A glimpse at dual-target drug development","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117418"}}